Latest News
Nov 13, 2017

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the submission of a New Drug Application (NDA) to the U.S. Food and...

Nov 10, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced that it is voluntarily delisting the company's ordinary shares from trading on the Tel Aviv Stock Exchange (TASE). Under Israeli law, the delisting...

Nov 9, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Clofarabine Injection, 20 mg/20 mL (1 mg/mL) Single-Dose Vials, a generic version of Genzyme's Clolar®. Mylan received final...

Nov 6, 2017

Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2017. Third Quarter 2017 Financial Highlights Total revenues of $2.99...

Nov 1, 2017

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional positive efficacy data from the...

View More


Search News Releases

Contact Mylan Communications

Global Communications 
724.514.1968
communications@mylan.com

Stay Connected